Pfizer and BioNTech begin global phase II/III COVID-19 vaccine trial

After reviewing preclinical and clinical data from phase I/II clinical trials and discussions with FDA and other countries’ regulators, BNT162b2, an mRNA product, with mRNA encoding for SARS-CoV-2 full length spike glycoprotein (S) was selected to taken into larger studies.


Biospace Inc.